In December 2016, after nearly a year of preparations, Zhongdian Guokang was formally established based on the original innovation team. Although the company is rarely heard in the media, the shareholders behind it are the two central enterprises that are well-known and well-known: China Electronics and Sinopharm Leasing.

Behind the low-key, two major central enterprise shareholders

Zhongdian Guokang is a new Chinese medical service operator established by the Big Data National Team China Electronics and Medical Health Industry Corporation Sinopharm Leasing.

In August 2016, Nanjing established the China Healthcare Health Big Data Industry Alliance, and Mr. Xiao Xiaowu, Chairman of China Electronics, served as the chairman of the alliance. After two years of development, China's electronic big data sector has now aggregated more than 40 data sets in the health care field, including basic information on patients after desensitization, hospitalization, outpatient, physical examination, laboratory testing, Internet of Things, Internet-related more than 100 million pieces of data. More than 2 million pieces of data are added every day. At present, it has undertaken the city big data operation right of 1 province and 6 cities.

Sinopharm Leasing is the medical and financial sector of Sinopharm Group. With the mission of “helping national medical care and caring for human health”, relying on the superior brand advantage of shareholders, strong industrial background and strong financial strength, it has achieved a total scale of 100 for thousands of medical institutions. 100 million financial leasing, 1 billion commercial factoring, dozens of hospital equity investment, over 100 million Internet finance medical financial services, in the future will provide more comprehensive, professional, one-stop for more institutions and enterprises in the health care industry chain Financial services.

An experienced and innovative team

Since 2012, the core team of CEC Guokang has started “ mobile medical care , chronic disease management, cardiovascular follow-up, and then regional population health big data platform business”, focusing on the high-tech fields in the emerging medical and health industry.

The innovation team comes from multi-disciplinary companies such as big data, medical information , Internet medical care, insurance control fees, and pharmaceutical industry. It has a mix of medical big data , medicine and medical insurance, and has strong innovative practice ability.

Positioning: New medical service operators

CLP Guokang supports the remote medical treatment, chain pharmacies and urban residents of the medical institutions through the cloud platform API of “Artificial Intelligence Algorithm Library + Big Data Platform” to realize medical cloud services, medical services and medical services, and to shape new medical service operators. :

1. Full lifecycle management from medical care to health;

2. All-field medical services from in-patient medical treatment to out-of-hospital follow-up;

3. From the diagnosis and treatment, drug distribution, remote testing and inspection to the full industrial chain supply of medical insurance.

When talking about the company's positioning, founder Liu Junhui said that purely online or offline can not meet the user's health and medical needs, only to give full play to the innovative team's online genetic and shareholder resources to build sufficient Competitive advantage is good for users. Zhongdian Guokang has chosen to cooperate fully with second- and third-tier cities, use shareholder advantage to acquire equity in some hospitals, build an independent third-party medical center, place equipment and platform assets for hospitals, and lay out offline resources. At the same time, give full play to medical health big data. Platform advantage, with platform API advantages to empower hundreds of medical institutions, hundreds of chain pharmacies and millions of residents, using online platforms to provide telemedicine services, prescription and drug services, HMO chronic disease insurance services, etc. The B2B2C model can bring a batch of effective C-end users, which is huge compared to pure B2C Internet medical C-end users.

Emerging business under supply-side reform

"With the people's longing for healthy living and the tide of new medical reforms, most cities need to systematically reconstruct the existing medical system. This requires reform of the supply side, medical services and insurance services. The positioning of Zhongdian Guokang is a new type of medical service operator."

Liu Junhui emphasized that the core idea of ​​supply-side reform: after the change of production mode, it is more conducive to the development of productivity. CEC Guokang compliant with the medical reform policy and continuously reconstructed through the “cloud+AI” empowerment method including the population health big data platform. The original product line, such as operation, AI-based medical platform operation, AI-based rehabilitation specialist service operation, etc., also innovated and launched the "blockchain-based prescription circulation platform" product and "chronic disease HMO platform" products.

"The blockchain-based prescription circulation platform" subverts traditional medicine circulation methods and accelerates medical improvement

The main theme of the new medical reform policy is the grading diagnosis and treatment and the reduction of drug expenditure. How to effectively manage the prescription behavior of doctors is a key point for the next policy. The evolution to PBM based on rational drug use is the future trend. Based on this background, CLP Guokang independently developed the "blockchain-based prescription transfer" product, which was released in January 2018. It has already cooperated with nearly ten large-scale top three hospitals, and has the largest telecom operators and the largest medical informationization in China. The manufacturer signed a strategic agreement and the product has been piloted in Shandong Province and Anhui Province. The product has three highlights:

"Prescription Transfer" service function

According to Liu Junhui, in foreign countries, doctors with prescription rights prescribe a prescription, which is the doctor's work and products, and is charged to the patient or outside the hospital. In China, in a sense, the prescriptions prescribed by doctors are “private” outflows, and there is no authoritative shared circulation platform. In theory, all prescriptions prescribed by doctors should be shared through a platform that guarantees the safety of all prescriptions and ensures that all prescriptions cannot be tampered with, such as a prescription flow to the Internet and eventually to a pharmacy or distribution company. If tampering occurs, it will become a medical accident.

The combination of CLP Guokang's choice of blockchain technology and prescription circulation has two advantages:

First, the use of encryption technology and non-tampering technology to ensure the high security of data transmission process over the Internet;

Secondly, the smart contract technology solves the problem of the pharmacy's account period. CEC Guokang embeds the blockchain-based smart contract technology into the bottom layer, and packages the drug receivables into digital assets, which are provided to the funded funds, such as banks. Capitalists such as factoring companies and internet finance companies solve the problem of the accounting period of industrial enterprises (pharmaceutical companies) to circulation enterprises (pharmacies, etc.). Solve the problem of circulation funds for pharmacies and drug circulation enterprises, and help the development of the industry and the timely and stable supply of medicines.

"reasonable medication" service function

Prescriptions must be reviewed online during the passage of the prescription. In practice, some chronic diseases and common diseases will prompt doctors to prescribe large prescriptions, and some issues such as incompatibility taboos need to be paid attention to. As a powerful data gene company, CEC Guokang will carry out in-depth collation and research on medical data assets shared with shareholder companies and cooperative hospitals, and develop rational drug use functions into the prescription circulation platform. When the prescription data arrives at the pharmacy, it will run on the platform of the trial. If the prescription issued by the doctor does not have reasonableness or supernormal medication or triggers the contraindication rules, a corresponding interface will pop up to remind the doctor, then the doctor can The prescription is adjusted.

"Pharmaceutical-based supply chain finance" service function

The service is under development, and the service is mainly to embed the blockchain smart contract just mentioned at the bottom of the prescription platform. CLP Guokang shareholders have a factoring license and have 10 billion funds to serve the supply chain finance, so that they can give full play to their advantages and serve more customers.

According to Liu Junhui's summary, medical finance has nearly seven innovation directions, one of which is an important supply chain finance based on medicines and consumables. In the future, there will be 100 billion prescription drugs on the Internet for medical treatment, so there will be many innovations and business restructuring in medical supply chain finance.

"Severe disease management and dispensing medicine" service function

The prescription circulation is mainly the chronic disease and outpatient medication in the outpatient department. This part can be completely separated from the top three hospitals and placed in the primary medical institutions. But from an economic point of view, putting nearly a thousand drugs in primary health care institutions is very uneconomical and violates economic principles. The normal way of circulation is to see the doctor at the grassroots level, and the dispensing is done through the Internet.

This is also the core idea of ​​supply-side reform: after the transformation of production methods, it is more conducive to the development of productivity.

The so-called strong grassroots layer is to move all outpatient medications and chronic disease medications to the Internet for diagnosis and treatment, and move to the grassroots for the first diagnosis and follow-up. As a result, all medical and medical expenses will be reduced and efficiency will increase. Among them, there are reforms of doctors' treatment methods, as well as reforms of drug distribution methods and disease management methods.

Medical improvement into a new phase, HMO products are just around the corner

Based on the judgment of the big environment, in March 2018, Zhongdian Guokang released a chronic disease HMO product. At present, the program has started cooperation in many cities across the country.

“At the beginning of the company's establishment, we had in-depth communication with the mainstream commercial insurance company and laid out the HMO business.” In March 2018, CLP Guokang released the chronic disease HMO product program and started in many cities. Cooperation.

The typical case of HMO in the United States is Caesars Medical. The core essence is that an insurance-licensed medical institution provides insurance services to residents. The insurance services cover medical services. You can choose hospital grade, doctor level, medical treatment location, drug type, etc. It is a medical package service.

Some domestic enterprises have been doing it, and the results have been minimal. The main reason is that the medical reform policy was not yet available. In recent years, the new medical reform policy has made many HMOs possible in China, and it is necessary to consider reducing operating costs. HMO providers make the current remote diagnosis and treatment of chicken ribs necessary. HMO providers have many barriers to break, need insurance background, strong control ability, medical service ability, and even need to acquire hospitals to achieve closed-loop effect. .

The establishment of the National Health Insurance Agency is a very important signal. From the pricing of the National Development and Reform Commission to the recruitment of the Health Planning Commission, including the payment made by the former Ministry of Human Resources and Social Security, all of the services covered by the Medical Security Bureau cover the entire chain of services from pricing to procurement to payment. This kind of layout is very conducive to decision-making, which is conducive to medical insurance pricing, procurement and payment methods for medical reform. This is the perfect time to develop HMO.

Through the above-mentioned products, CEC Guokang hopes to implement classified medical treatment, reduce the burden of medical treatment for large-scale top three hospitals, save the national chronic disease medical insurance fund, and form a new supply of medical and medical services in the form of “Internet + health” to realize supply-side reform.

Kombucha PH Test Strips

Drinking tea is a kind of drink originating in China made from the leaves or buds of the tea plant. Also refers to the leaves of the evergreen shrub tea tree that can be used for drinking tea, and drinks made with these leaves, and later extended to all herbal tea made with plant flowers, leaves, seeds and roots, such as "Tieguanyin" and so on.
Tea, as a famous health drink, is the contribution of the southern Chinese people to the Chinese food culture and the Chinese people's contribution to the world food culture

Kombucha Ph Test Strips,Kombucha Ph Strips,Kombucha Test Strips,Ph Tester For Kombucha

Changchun LYZ Technology Co., Ltd , https://www.lyzinstruments.com